Abstract 17636: Low Rates of Oral Anticoagulation Use Among Patients Hospitalized With Atrial Fibrillation and at High Risk for Stroke
Introduction: Despite an increased risk of stroke with atrial fibrillation (AF), outpatient prescription data suggest approximately half of AF patients with guideline indications for oral anticoagulants (OAC) remain untreated. We performed a retrospective analysis using the Premier Healthcare Database, representing 1 in 5 U.S. discharges, to assess inpatient OAC use at discharge among patients hospitalized with AF.
Methods: Included patients were age ≥ 40 years, admitted between January 2010 and June 2015 with a primary or secondary AF diagnosis, CHA2DS2-VASc score ≥2, and length of stay (LOS) >1 day. Those with a history of heart transplant, mechanical heart valve replacement, any bleed during admission, open heart, brain or spinal surgery or discharge status of left against medical advice, hospice, transfer to another acute care facility, or expired were excluded. The primary measure was OAC use at discharge defined as at least one charge the day before and/or day of discharge for warfarin or a non-vitamin K antagonist (rivaroxaban, apixaban, dabigatran or edoxaban).
Results: Among 1,579,456 admissions in 812 US hospitals, 46.2% of inpatients with AF received an OAC at discharge, and rates were consistent across a diverse set of patient subgroups (Figure). The median age at admission was 78 (IQR 69-85) years, and patients were 53% female and 81% Caucasian with a history of prior stroke (19%), hypertension (89%), heart failure (51%), and diabetes (41%). Median CHA2DS2-VASc score was 4 (IQR 3-5). Admissions were mostly in hospitals within urban settings (86%) and designated as non-teaching (60%). Median LOS was 4 (IQR 3-7) days. Aspirin use was documented alone in 14% or in combination with OAC in 14%.
Conclusions: Fewer than 1 in 2 patients hospitalized with AF and a guideline indication for anticoagulation for stroke prevention received an OAC at discharge. This low rate of OAC use in hospitalized patients highlights an important opportunity to improve care in AF patients.
Author Disclosures: S.D. Pokorney: Research Grant; Modest; Boston Scientific, Gilead. Consultant/Advisory Board; Modest; Boston Scientific, Medtronic. E.M. Hylek: Honoraria; Modest; Boehringer Ingelheim, Bayer. Consultant/Advisory Board; Modest; Daiichi Sankyo, Ortho-McNeil-Janssen, Johnson & Johnson, Boehringer- Ingelheim, Bristol-Myers Squibb, Roche, Pfizer. J. Fastenau: Employment; Significant; Janssen. J. Davidson: Employment; Significant; Janssen. C. Damaraju: Employment; Significant; Janssen. B.R. Shah: Employment; Significant; Premier Inc. R.A. James: Employment; Significant; Premier Inc. J.A. House: Employment; Significant; Janssen. C.B. Granger: Research Grant; Modest; Armetheon, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Bayer, Daiichi Sankyo, Janssen, GlaxoSmithKline, Medtronic Foundation, Sanofi-Aventis, The Medicines Company. Consultant/Advisory Board; Modest; AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, GlaxoSmithKline, Roche, Janssen, Lilly, Sanofi-Aventis, The Medicines Company.
- © 2016 by American Heart Association, Inc.